source
- FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitationThe U.S. Food and Drug Administration has granted approval to Axsome Therapeutics’ oral medication Auvelity for the treatment of agitation in patients with Alzheimer’s disease. Axsome noted that a…
- Summit Therapeutics shares tumble 20% after interim Phase 3 miss for ivonescimabSummit Therapeutics saw its shares fall about 20% after the market close on Thursday. The decline came after an interim analysis of a Phase 3 trial for its cancer candidate ivonescimab failed to m…